Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases.

See more

SEPTEMBER 19, 2019

Biophytis to Present at 15th International Pharma Licensing Symposium in Paris. Read the Press Release

AUGUST 23, 2019

Biophytis has signed €24m bond funding from Negma to continue the development of its drug candidates to treat neuromuscular diseases. Read the Press Release

AUGUST 8, 2019

Shareholders Aprove All Resolutions of the Extraordinary General Meeting held on August 8, 2019. Read the Press Release

Our science

Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.

See more


Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.

See more



Biophytis has been listed on the market Euronext Growth Paris
since July 13, 2015.

ISIN : FR0012816825
Ticker: ALBPS
Type of listing : continuous
Number of outstanding shares: 13,463,413
Eligible for PEA and PEA-PME equity saving plans

Click here for live stock price

See more